Isatuximab for multiple myeloma with 1q21 abnormality
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if adding the drug isatuximab to standard treatments helps people whose multiple myeloma has returned or stopped responding, especially if their cancer cells have an extra copy of a certain gene (1q21). The study checks how well these drugs work together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have multiple myeloma that came back or did not respond to at least one prior treatment, including isatuximab
- Doctors have checked your cancer cells for a genetic change called 1q21, either when you were first diagnosed or when it came back
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests isatuximab (an anti-cancer antibody) combined with other study medicines in people whose multiple myeloma has come back or not responded. It aims to improve control of the disease after you’ve already had multiple prior treatments.
This trial tests a new drug called QI-019A for people whose multiple myeloma has returned or stopped responding to at least two prior treatments. The goal is to see if it is safe and if it can help control the disease.
This trial tests a new drug called QI-019B for people with multiple myeloma whose cancer has come back or stopped responding to other treatments. The goal is to see if it is safe and can help shrink or slow the cancer.
This trial tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone—for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding isatuximab helps control the cancer better.
This trial tests a new combination of three drugs (F182112, isatuximab, and lenalidomide) for people who have just been diagnosed with multiple myeloma and have had little or no prior treatment. The goal is to see if this combination is safe and effective in controlling the disease.
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
Hear when a new Multiple Mieloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.